As we observed a tumor antigen-specific CD8+ T-cell response in the early phase of BRAFi therapy and cDC1 are reported to be the best cross-presenting DC subset, we wanted to assess the contribution of cDC1 to T cell immunity during BRAFi therapy. The gene discussed is CD8A; the disease is neoplasm.